Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05066464 |
Other study ID # |
APHPHLJ |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
November 29, 2021 |
Est. completion date |
April 28, 2022 |
Study information
Verified date |
September 2021 |
Source |
Assistance Publique - Hôpitaux de Paris |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
With 25.2 million children affected and 3.4 million deaths in 2017, paediatric sepsis is the
leading cause of under-five mortality worldwide and has recently been described as
"significant global health threat" by the World Health Organization. In addition to early
antibiotics, fluid bolus therapy (FBT) is one of the cornerstones of management, due to the
theoretical improvement of cardiac output, oxygen delivery and organ perfusion. In the
absence of a consensual and operational definition to date, the latest international
guidelines of the Surviving Sepsis Campaign 2020 (SSC-2020), refers to children (≥ 37 weeks
gestation at birth to 18 years old) with severe infection leading to cardiovascular (i.e.,
"septic shock") or non-cardiovascular organ dysfunction (i.e., "other sepsis-associated organ
dysfunction" or former "severe sepsis"). The SSC-2020 specifies the modalities for paediatric
sepsis management, particularly concerning FBT, with, for example, the preferential use of
balanced crystalloids, and a target volume of 40-60ml/kg at one hour of recognition using
boluses of 10-20ml/kg in children who have access to a paediatric intensive care unit (PICU)
in their health system. Further, it is now well established that compliance with
international guidelines is associated with improved outcomes in paediatric sepsis. Despite
the importance of awareness and implementation of the SSC-2020, there are, to our knowledge,
no studies evaluating its application in children. We prospectively conducted the Fluid
Resuscitation for Suspected Sepsis in Paediatric Emergency Departments (FRESSPED) study in 25
hospitals over five weeks between November 2021 and March 2022, whose principal objective was
to assess doctors adherence to the SSC-2020 guidelines when performing FBT in infants and
children with suspected sepsis in French paediatric emergency departments.
Description:
FRESSPED study was conducted over 5 weeks, the last week of each month, between November 2021
and March 2022 (11/29 - 12/05 ; 12/27 - 01/02 ; 01/24 - 30/01 ; 02/21 - 02/27 ; 03/21 -
03/27). Patients were followed up one month after inclusion, extending the study period until
midnight on 28 April 2022.
FRESSPED study was conducted in three stages :
1. Evaluation of usual fluid bolus therapy practice in infants and children with suspected
sepsis in French paediatric emergency departments, through the prospectively anonymous
completion of a paper case report form (CRF) designed to be completed in less than 5
minutes, within 72 hours of inclusion, by each doctor in one of the participating
centers caring for an eligible patient
2. Questioning of participating doctors at the end of the 5-week prospective data
collection period, to explore the underlying reasons of doctors non-adherence to the
SSC-2020 guidelines. It will take the form of a short, anonymized and blinded of centers
outcomes, online survey to assess attitudes and knowledge, without inter-center or
inter-individual comparisons (except for doctors seniority)
3. Description of characteristics and outcomes of included patients, by consultation, up to
1 month after inclusion, of data collected in routine care (patient chart) by the lead
researcher (Julian San GEROTEO).
In addition to the above criteria, the suspicion of sepsis was confirmed retrospectively in
doubtful or non-documented cases or those without microbiological documentation, using an
adjudication committee composed of two medical experts particularly important in the absence
of a ""gold standard"" definition of paediatric sepsis to date.